Table 3 Bronchoalveolar lavage fluid (BALF) and peripheral blood cellularity in patients with severe/critical COVID-19
| Â | Total patients | Patients with ARDSa/critical pulmonary infection (IMVb) | Peripheral blood cellularity | BALF cellularity or lung biopsy |
|---|---|---|---|---|
Wu C et al. JAMA Int Med 2020 [13] | 201 | 84 (N = 6, 2.9%) | >Neutrophils < TCD4+ and TCD8+ | No data |
Chen T et al. BMJ 2020 [12] | 274 | 196 (N = 17, 6.2%) | < Lymphocytes >Neutrophils | No data |
Chen G et al. J Clin Invest 2020 [21] | 21 | 11 (N = 0) | < Lymphocytes >Neutrophils | No data |
Tang X et al. Chest 2020 [23] | 73 | 36 (N = 14, 19.2%) | < Lymphocytes (TCD4+ and TCD8+) | No data |
Liao M et al. Nature Medicine 2020 [7] | 9 | 6 (n.a.c) | No data | >Macrophages >Neutrophils < T and NK Lymphocytes |
Xu Z et al. Lancet Resp Med 2020 [14] | 1 | 1 (N = 1, 100%) | < TCD4+ and TCD8+ Activated Lymphocytes (HLA-DR+) | >Lymphocytes |
Tian S et al. Mod Pathol 2020 [8] | 4 | 4 (n.a.) | < Lymphocytes | >Mononuclear cells |
Carsana L et al. Lancet Infect Dis 2020 [24] | 38 | 38 (n.a.) | No data | >Macrophages >Lymphocytes |